news
Lynparza® with abiraterone delays prostate cancer progression
Lynparza with abiraterone is the first PARP inhibitor to demonstrate clinical benefit in combination with a hormonal agent in this setting.
List view / Grid view
metastatic castration-resistant prostate cancer (CRPC)
news
EC approves Xtandi™ for third prostate cancer indication
Xtandi™ (enzalutamide) was approved for metastatic hormone-sensitive prostate cancer after it reduced the risk of radiographic progression or death by 61 percent in a trial.
news
Immunotherapy vaccine shows promise in prostate cancer patients
The multi-targeted hAd5 immunotherapy vaccine was found to be safe and showed initial signs of efficacy in patients with advanced metastatic castration-resistant prostate cancer.
news
Erleada drug combination extends progression-free survival in prostate cancer trial
In the Phase III ACIS study, prostate cancer patients treated with a combination of Erleada® and Zytiga® plus prednisone were less likely to die than participants receiving Zytiga and prednisone.
news
First-in-human universal CAR-T therapy trial begins
The dose-finding trial will evaluate the safety and activity of UniCAR-T-PSMA in up to 16 patients with advanced relapsed/refractory, PSMA-positive solid tumours.
news
FDA approves Lynparza (olaparib) for HRR mutated prostate cancer
Lynparza’s approval was based on results from a Phase III clinical trial in which it improved overall survival and progression-free survival in patients with certain prostate cancers.
news
Enzalutamide treatment approved for use in China
The Chinese National Medical Products Administration has given its approval to XTANDI® to treat prostate cancer, following a successful Phase III trial.